Terbinafine Clinical Indications
Terbinafine is primarily used for treating fungal nail infections (onychomycosis) and scalp ringworm (tinea capitis), with FDA approval specifically for onychomycosis caused by dermatophytes. 1
Primary FDA-Approved Indication
- Onychomycosis (fungal nail infections) of the toenail or fingernail caused by dermatophytes (tinea unguium) 1
First-Line Treatment for Dermatophyte Infections
Terbinafine should be considered the first-choice systemic antifungal for dermatophyte onychomycosis based on superior efficacy and tolerability compared to alternatives. 2
Onychomycosis Treatment Superiority
- Achieves 55% complete cure rates (mycological clearance + normal nail) versus 26% with itraconazole at 72 weeks 2
- Long-term 5-year data shows 46% sustained mycological cure versus 13% with itraconazole 2
- Significantly lower relapse rates (21-23%) compared to itraconazole (48-53%) 2
Tinea Capitis (Scalp Ringworm)
- Terbinafine is more efficacious against Trichophyton species (T. tonsurans, T. violaceum, T. soudanense) 2
- Dosing by weight: 2
- <20 kg: 62.5 mg daily for 2-4 weeks
- 20-40 kg: 125 mg daily for 2-4 weeks
40 kg: 250 mg daily for 2-4 weeks
- Important caveat: Griseofulvin remains more effective for Microsporum species (M. canis, M. audouinii) 2
- Shorter treatment duration (2-4 weeks) compared to griseofulvin (6-8 weeks) improves compliance 2
Additional Dermatophyte Infections
Terbinafine demonstrates excellent efficacy for various superficial fungal infections: 3, 4, 5
- Tinea pedis (athlete's foot): >80% mycological cure rates 3, 5
- Tinea corporis/cruris (body/groin ringworm): >80% mycological cure rates 3, 5
- More effective than griseofulvin and ketoconazole for these indications 3, 4
Mechanism and Spectrum of Activity
- Fungicidal mechanism: Inhibits squalene epoxidase, causing ergosterol depletion and toxic squalene accumulation 2
- Broad spectrum against dermatophytes, particularly Trichophyton rubrum and T. mentagrophytes 2, 4
- Limited activity against Candida species (fungistatic only) 2, 3
- Persists in nails for 6 months after treatment completion due to lipophilic properties 2
Emerging Resistance Concerns
A critical pitfall: Trichophyton indotineae (formerly T. mentagrophytes genotype VIII) shows significant terbinafine resistance due to SQLE gene mutations. 6, 7
- Emerging in Europe after spreading from the Indian subcontinent 7
- MICs ranging from 0.014 to ≥16 μg/mL 7
- Consider molecular diagnosis in patients with: 6
- Extensive dermatophytoses
- Treatment failure history
- Recent travel to endemic areas
- Itraconazole serves as the primary alternative when resistance is confirmed 7
Investigational and Off-Label Uses
While not FDA-approved, terbinafine shows potential efficacy in: 8, 9
- Chromoblastomycosis (useful first-line treatment) 9
- Sporotrichosis (cutaneous and lymphocutaneous forms) 8
- Pulmonary aspergillosis 9
- Various subcutaneous mycoses (phaeohyphomycosis, maduromycosis) 8
Safety Monitoring Requirements
Critical monitoring parameters before and during treatment: 2
- Contraindicated in active or chronic liver disease 2
- Baseline liver function tests and complete blood count required for: 2
- Heavy alcohol consumption history
- Hepatitis history
- Hematological abnormalities
- Pediatric patients (not licensed for pediatric onychomycosis)
- Warn patients about permanent taste disturbance risk (rare but can be permanent) 2
- Minimal drug interactions except with CYP450 2D6 substrates 2